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Abstract
Background: Liver cancer is the fifth most common cancer in men and the seventh for women. Usually because
of late diagnosis, the prognosis for liver cancer remains poor, resulting in liver cancer being the third most
common cause of death from cancer. While some countries have treatment guidelines, little is known or
understood about the strategies needed for liver cancer control internationally.
Objective: To explore leading liver cancer clinician’s perceptions of the current public policy needs to control liver
cancer internationally.
Methods: Key informant interviews were conducted with a range of liver cancer clinicians involved in policy in
eleven countries. Interviews were digitally recorded, transcribed verbatim, translated (where necessary), de-
identified and analyzed by two researchers using a constant comparative method.
Results: Twenty in-depth semi-structured interviews were conducted in: Australia, China, France, Germany, Italy,
Japan, Spain, South Korea, Taiwan, Turkey and the United States. Nine themes were identified and cluster into
three groups: 1) Promoting prevention via early risk assessment, focusing on viral hepatitis and other lifestyle
factors; 2) Increasing political, public and medical community awareness; and 3) Improving funding for screening,
liver cancer surveillance and treatment.
Conclusion: This study is an important step towards developing an evidence-based approach to assessing
preparedness for implementing comprehensive liver cancer control strategies. Evaluation mechanisms to assess
countries’ performance on the needs described are needed. Future research will concentrate of understanding how
these needs vary across countries and the optimal strategies to improve the diagnosis and prognosis of patients
with liver cancer internationally.
Introduction
Liver cancer is the fifth most common cancer in men
and the seventh in women, because of its high fatality it
is the third most common cause of death from cancer
worldwide [1]. Hepatocellular carcinoma (HCC) is the
predominant histologic subtype compromising approxi-
mately 85-90% of all primary liver cancers [2]. In 2008
there were an estimated 695 000 deaths from HCC
globally among whom at least two thirds of these were
in the Asia Pacific region [3]. Most HCCs are discovered
late in advance stages due to the relative dearth of
symptoms in early stages and the rapid doubling of the
tumor [4]. Median survival of patients is estimated at
less than a year and less than five months without effec-
tive treatment [5].
Clinical guidelines have been developed by the Ameri-
can Association for the Study of Liver disease (AASLD),
the European Association for the study of the liver
(EASL), the Asian Pacific Association for the study of
the liver (APASL) and the Japanese society of hepatol-
ogy. According to these guidelines potentially curative
treatment for patients with early stage HCC include sur-
gical resection, percutaneous ablation and liver trans-
plantation. Fewer effective options are available for
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by Lin and Kao, the guidelines differ from one another
and further research is needed to develop best practice
guidelines for optimal management of HCC [10].
While clinical guidelines are important and sometimes
effective in standardizing care, [11] a broader scope is
needed to address what is described as a public health pro-
blem in need of cohesive strategies to ensure its proper
prevention, control and management [12]. Unlike clinical
guidelines, national policies for comprehensive liver cancer
control, from prevention, early detection, and treatment
are not widely available. Moreover, little is known or
understood about the current public policy needs for can-
cer prevention and control in many countries around the
globe. Furthermore a consensus statement from the Asian
Oncology Summit highlights the need for “policies direc-
ted at reducing risk factors for HCC” [13].
In recent years policy makers have acknowledged liver
cancer as a significant public health problem [3,13,14].
The real impact however, is clouded by the lack of reli-
able epidemiologic surveillance data. For example a
report from the European Hepatitis B expert group
noted the there is a scarcity of reliable epidemiological
data on hepatitis B, a leading cause of liver cancer [15].
Despite the calls to focus on these difficulties, the com-
plexities of liver cancer and the limited political and
public awareness make it complicated to identify the
most significant needs to address this growing problem.
This paper aims to identify the needs impacting liver
cancer research, prevention and treatment, especially
focused on hepatocellular carcinoma (HCC), across
Asia, Europe and North America. The study qualitatively
explored leading liver cancer clinician’s perceptions of
the current public policy needs to control liver cancer.
Methods
Respondents and recruitment
Key informant interviews were conducted with a range
of liver cancer clinicians purposively sampled on the
basis of being involved in policy and in liver cancer and
related disease prevention, detection, and management.
They were identified using the following criteria: i)
actively working in liver cancer in their country; ii)
involved in HCC clinical practice and policy or research;
iii) active members in national and international liver
associations and/or published extensively in peer review
journals. Potential respondents were informed about the
study via email or mail, and received a follow up tele-
phone call or email if they did not respond within two
weeks. The email or mail invitation was sent in English
as well as in the national language of the country, where
necessary. Upon a positive response, the interviewer
requested basic demographic information and scheduled
an appointment.
Data collection and analysis
An interview guide was used as a prompt sheet ensured
the same topics were covered during the interviews.
However questions were not asked in a standard way
and respondents were able to articulate their own per-
ceptions of current liver cancer policies and strategies to
advance liver cancer prevention, treatment and research.
Respondents were asked to comment on their countries’
current needs in combating liver cancer and major pol-
icy issues impacting diagnosis and prognosis.
Invitations to participate were sent to twenty five peo-
ple. The invitation outlined the objectives of the study,
explained the characteristics of the interview process
(open and flexible), informed participants about the
potential benefits and harms, ask for consent to record
the interview and informed about the founder of the
study and the lack of remuneration for participation.
In-depth, semi-structured interviews were carried out
between February and June 2010. The interviews were
conducted with individual respondents either in person
or by telephone in English or in the respondent’s native
language by trained fieldworkers with extensive experi-
ence conducting medical/scientific interviews in the
relevant countries. When conducted in the interviewee’s
native language, the field notes were immediately trans-
lated into English by the interviewer fluent in both lan-
guages. Interviews were digitally recorded, transcribed
verbatim, translated (where necessary), de-identified and
analyzed. One person refused and four other accepted
but were not interviewed as thematic saturation was
reached after the twentieth interview.
Preliminary data analysis was conducted after each
interview. This allowed identification of issues that
required further exploration in the interviews that fol-
lowed. Continuous analysis of collected data was per-
formed. After preliminary analysis was performed,
segments (paragraph, sentences) were coded and labeled
(i.e. data extracts from each transcript were grouped
together under the appropriate category). Coded seg-
ments were then compared for differences and similari-
ties of events and ideas. This process was repeated until
all comments were assigned to categories (constant
comparison) [16]. Data were validated in two different
ways. More than half of the interviews were coded on
two separate occasions to ensure consistency with the
coding. Categories were reappraised by the researcher to
judge whether any data had been misplaced (negative
case testing) [17].
Ethics
All participants were informed about the study and its
potential risks and benefits. Participation in the study
was voluntary and respondents were not reimbursed for
participation. The study was deemed exempt from
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University, Bloomberg School of Public Health Institu-
tional Review Board (IRB). Local experts were also con-
sulted to verify if any additional country specific
requirement needed to be met and the study also com-
plied with all local regulations.
Results
Twenty in-depth semi-structured interviews were con-
ducted with leading liver cancer clinicians in 11 different
countries: Australia (n = 1), China (n = 1), France (n =
1), Germany (n = 3), Italy (n = 1), Japan (n = 2), Spain
(n = 1), South Korea (n = 2), Taiwan (n = 1), Turkey (n
= 3) and the United States (n = 4). Interviews lasted
between 16 and 80 minutes (mean time 34 minutes)
and elicited a broad range of perceptions about public
policy needs to control liver cancer internationally. As
shown in Figure 1 three major themes emerged: the
need to promote prevention, increase awareness and
improve funding. Table 1 summarizes these themes and
the dimensions contained in each one. Each of the
themes and dimensions are further discussed in the fol-
lowing text.
Theme 1: Promote prevention
All participants described promoting prevention as an
important need in liver cancer control. There were three
dimensions of this theme: The need to prevent viral
hepatitis (primary prevention), early risk assessment for
HCC, and management of other risk factors. This is
summarized in one of the respondent’s quotes:
“Needless to say, prevention will reduce the number
of cases. Prevention of infection of hepatitis B and C
comes first. Next, prevention of cancer, screening,
complete cure treatment, prevention of reoccurrence,
and early diagnosis and treatment of reoccurrence:
This will eliminate cancer. So, prevention comes
first”.
Viral hepatitis
Prevention of hepatitis B and C virus (HBV and HCV)
infection was described by all respondents as an impor-
tant step towards reducing the incidence of HCC. Many
indicated that most countries in the study have a well-
established, nationwide vaccination program for HBV
with some countries already demonstrating reductions
of HCC and respondents expecting the incidence of
HCC to further decrease in the next 10-20 years. This
perception is supported by a 20 year follow up study of
hepatitis B vaccination in Taiwan [18]. However,
respondents also described that despite this, a vast num-
ber of people will still develop acute and chronic hepati-
tis B. In addition, even in countries with national
vaccination policies, respondents commented that there
still are portions of the population that may not be vac-
cinated or protected.
It is interesting to note that in one of the countries,
the uptake of hepatitis B vaccination is quite low
Figure 1 Current needs for liver cancer control.
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ception that vaccines are linked to neurological disor-
ders. The respondents in this country also commented
that these perceptions were fuelled by the media.
“The media and the newspapers several years ago
popularized the notion that the vaccine is responsible
for neurologic disorders. Therefore the vaccination
against HBV has been widely unpopular and has
been stopped at times”.
Participants described some high risk populations as
foreign born (especially from those countries where
hepatitis B vaccination was not available to them at the
time of their birth), and past or current injection drug
users. Therefore, control of both HBV and HCV is still
an issue in most countries. This is consistent with a
recent report by the Institute of Medicine (IOM) in the
United States which states that “unless action is taken to
prevent chronic hepatitis B and hepatitis C, thousands
more Americans will die each year from liver cancer or
liver disease related to these preventable diseases” [19].
Early risk assessment for HCC
The majority of respondents described “early risk assess-
ment” as paramount in liver cancer control. This was
considered by most as particularly important, consider-
ing that early detection and treatment of liver disease
have a major impact on HCC survival outcomes.
“We can actually identify the high risk patients and
use the well- developed screening strategies to moni-
tor these patients, so that these patients, if they ever
develop hepatocellular carcinoma, can actually be
diagnosed at the early stage, and treated...”
To enable the health care system to successfully inter-
cept and control liver disease at early stages, some
respondents call for primary care doctors to screen and
treat viral hepatitis and also to screen for and manage
risk factors associated with liver cancer. “Primary care
doctors need to be sensitized to the risk of liver disease,
the implications, the detection in particular of viral
hepatitis, the treatment options, or the need to refer, and
ultimately screening for liver cancer”.
Most respondents described that liver cancer is rarely
detected at an early stage, limiting the amount and
effectiveness of treatment and other efforts to better
manage it. As noted by one participant “half of the cases
of HCC are diagnosed outside of screening programs,
which is an incredibly low figure - meaning that patients
are not detected in early stages”.
Other risk factors
A number of respondents described that besides heavy
alcohol consumption, obesity and diabetes are risk fac-
tors that could be modified and have an impact on
HCC incidence. Non-alcoholic steohepatitis (NASH)
was also mentioned as an important risk factor. Some
respondents noted that thanks to vaccination and better
needle exchange practices, alcohol-induced hepatitis,
obesity, diabetes mellitus and metabolic syndrome will
be the main causes of liver cancer in the future. How-
ever various respondents mentioned that more research
is needed to understand this relationship as these condi-
tions often occur in tandem. Consistent with the




Viral hepatitis “You really need to work backwards in the spectrum of the disease so you are detecting more early disease and
either curing Hep C or preventing Hep B both of which will eventually lead to a decreased incidence of HCC”.
Early risk
assessment




“Part of the problem is that the prevalence of obesity continues to rise, it may have leveled off now, but until now it
has been rising precipitously so that there will presumably be a lag period during which patients who are obese and





“...on a national basis the government has no strict plan for HCC and this is a big issue”.
Clinical
education
“Primary care doctors need to be sensitized to the risk of liver disease, the implications, the detection in particular of
viral hepatitis, the treatment options, and the need to refer, and ultimately screening for liver cancer”
Public
awareness
“There is a total absence of public awareness as best as I can tell. I am not there with my finger on the pulse of the
public, but it’s fairly clear that this never gets on the radar the way breast, colon, melanoma, pancreas, and other
common cancers do”.
Improve funding Screening “There’s a clear need for screening of cirrhotic patients. Screening is expensive......”.
Treatments “...the new and expensive drugs and technologies are an exception. So many patients complain, many patients ask
for a new technology or a newly developed drug and treatment. However they are not covered by insurance, so
that’s a big problem”.
Surveillance “a more concerted effort to coordinate with [Ministry of Health] and to develop more robust prevalence data about
viral hepatitis worldwide”.
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increased incidence of HCC in patients with non-alco-
holic fatty liver disease (NAFLD) which is associated
with metabolic syndrome, obesity and insulin resistance
[20].
“I would say the first thing is really to improve the
awareness with regard to potential risk factors. These
include the obvious, hepatitis infection with B and C,
lifestyle modification to reduce alcohol, and make
sure that we know the epidemiology trend for non-
alcoholic fatty liver disease and the potential impact
on HCC incidence”.
Theme 2: Increase Awareness
The second theme that emerged from interviews with
the key informants was centered on increasing aware-
ness. Participants commented that liver disease and
HCC knowledge and awareness was poor amongst three
different groups: politicians, the general public and doc-
tors.
“The low level of provider knowledge around viral
hepatitis...that is a cascade of problems, people not
getting vaccinated, people not getting information
about the value of screening, people not getting
screened, misinterpretations of diagnostic or screening
tests, misinformation like hepatitis B is not going to
kill you, it’s in an inactive state, etc. and then refer-
rals not being made to treatment centers to get
treatment”.
Political awareness
Most respondents considered that chronic hepatitis B
and C need to be recognized as an important public
health problem, but that due to other, more acute health
priorities and well-coordinated public and political
demand, it is hard to gain support of policy-makers and
political bodies involved in supporting funding and
prioritizing liver cancer.
“The principal gap for HCC is the absence of a com-
mon policy in all regions [of the country].”
“Liver cancer is not regarded as a major health pro-
blem. It is regarded as a rare cancer. There are no
public policy initiatives”.
“The lack of a national approach” was quoted by some
of the respondents. This was sometimes linked to the
lack of accurate data on incidence and prevalence, but
more often mentioned as related to the lack of a well-
c o o r d i n a t e da n dl i n k e de f f o r tb yd i f f e r e n ti n t e r e s t sa n d
initiatives related to liver disease.
Public awareness
The majority of respondents commented that visibility
for liver cancer is low compared to other major cancers
such as colon, breast, and lung. The public’su n d e r -
standing of liver cancer and knowledge about the risk
factors were described as limited. “There’sa b s o l u t e
ignorance among [the] common population and there is
a clear need for education”.
According to most respondents, public awareness
must be increased “to let people know that chronic liver
disease is a major risk factor for HCC”.P u b l i ch e a l t h
campaigns are needed to stress the importance of know-
ing risk factors and to encourage early detection of liver
disease and cancer. Several respondents noted the
importance of health campaigns and media exposure to
increase awareness amongst the general public about
chronic viral hepatitis. Some respondents attributed the
lack of public awareness to the absence of advocacy.
“There are more gaps than advocacy at this point,
meaning that there is certainly no coordinated public
awareness; there’s barely awareness of hepatitis
screening, detection, and treatment”.
Clinical education and awareness
Some of the respondents mentioned that the medical
community at large should be educated. Several respon-
dents specifically referred to the need to educate doctors
in primary care settings to proactively asses and manage
liver disease risk factors, and also to refer such patients
to centers of excellence in hepatology and liver cancer.
“Primary care doctors need to be sensitized to the risk
of liver disease, the implications, the detection in par-
ticular of viral hepatitis, the treatment options, or the
need to refer, and ultimately screening for liver
cancer”.
Theme 3: Improve funding
T h et h i r dt h e m ew a sfunding including dimensions
related to funding and reimbursement of screening, sur-
veillance and treatments.
Screening
As previously stated, some respondents described the
need for nationwide screening programs for HCC. A
number of respondents mentioned screening both for
viral hepatitis and also “screening for cirrhosis [Non-
HBV] in the general population”.S e v e r a lr e s p o n d e n t s
considered that resources need to be better allocated for
such programs. Increased political (government) aware-
ness and the development of mandatory screening
guidelines and systems would improve this process.
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the government level... funding is a major
consideration”.
Bruix and Llovet described how HCC meets most of
the criteria that justify a screening program: “the popu-
lation at risk is known, the disease is highly prevalent, it
has a high mortality, and effective screening tests are
available and acceptable” [21]. However as stated by
some respondents and identified in the literature, there
are issues around sensitivity and specificity of screening
tests (i.e. Alpha-Fetoprotein (AFP)), the screening inter-
val and the impact of screening on HCC survival [22].
Furthermore Gomma al colleagues have identified that
although there is an international consensus on the
diagnostic pathway for HCC, there is no “ideal screening
modality” [23].
Surveillance
Most respondents also identified the need for surveil-
lance to document the incidence and prevalence as well
as the burden of liver disease and cancer. Current efforts
to collect data seemed to be supported by “champions”
and on a voluntary basis. “We have already started a
nationwide liver cancer registry, for more than five years
now. It is voluntary data. More than 20 institutes are
taking part. But because of a limited budget, actually, it
is not so active.” H o w e v e ri ti si m p o r t a n tt on o t et h a t
some countries do collect data in a systematic and com-
prehensive way. Consistent with the views given by the
respondents about the importance of surveillance, a
study on HCC screening conducted by Zhang et al,
found that surveillance of hepatitis B carriers in shang-
hai, China reduced HCC related mortality by 37% [22].
Treatments
Some respondents reported the lack of insurance cover-
age for “targeted therapy”. A number of respondents
noted that new therapies are likely to have a high cost,
thus limiting patient access.
“The advent of many new drugs will hike up the
medical cost and, since these drugs are produced by
foreign pharmaceutical companies, the money [name
of the Country] will flow out of the country. There-
fore, I think this will have a serious effect on the pol-
icy of medical costs”.
Most respondents described the importance of collect-
ing the “appropriate data” which could inform policy
makers about the social burden of the disease and allow
them to allocate resources into prevention and control
of liver disease and cancer.
“We don’t yet have a generally accepted surveillance
strategy to detect and uncover patients with
increased risks, nor have an organized surveillance
program in which these individuals could enter to get
regular check-ups of the liver.”
Further discussion
Even though there are differences in terms of resources,
the etiology of the disease and access to health care, the
needs for liver cancer control and implications for policy
described by the respondents in this study were similar.
In particular, some respondents consider there is still a
need for a global (international approach) to liver cancer
control. “An authority [such as] the World Health Orga-
nization, can institute some coordinated (approach) with
the government policies within individual countries.”
Even this may not be enough. Some of the respondents
recommended having a global approach that raises
awareness about the disease.
“I think you need to let the message out, because I
think people need to know how significant this dis-
ease is, both here and globally. I think we need to
have some comparison about the outcome and how
m a n yl i v e sw ec a ns a v ei fw ei m p r o v et h ep u b l i c
awareness for liver versus some other more common
cancers. Hopefully...we can do this kind of compari-
son so that people all of the sudden realize this dis-
ease may not be as trivial as people thought”.
It is important to note some limitations in the study.
First, it was conducted among leaders from a limited set
of countries and, consequently, the findings may differ
in other country settings. Second, reporting of needs in
liver cancer care, and policy may have been influenced
by respondents’ greater knowledge of one area as
opposed to other areas. Thirdly, a greater diversity of
respondents may identify additional needs and suggest
further strategies for a more systematic approach to
liver cancer control.
Conclusion
According to the stakeholders in this study, different
needs (improve prevention, awareness, funding) were
identified to formulate a comprehensive liver cancer
control strategy. Even though health policy varies from
country to country and different countries have specific
needs and views, this study showed that there were
more common than dissimilar needs in the countries
that participated. The “needs” identified by the respon-
dents refer to the gaps in prevention, treatment of liver
disease and other strategies necessary to achieve liver
cancer control.
To our knowledge this is the first study explore leading
liver cancer clinician’s perceptions of the current public
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exploratory study is an important step towards developing
an evidence-based approach to assessing preparedness for
implementing comprehensive liver cancer control strate-
gies. Evaluation mechanisms to assess countries’ perfor-
mance on the needs described are needed. Future research
will concentrate of understanding how these needs vary
across countries and the optimal strategies to improve the
diagnosis and prognosis of patients with liver cancer inter-
nationally via a. a quantitative survey.
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Appendix 1. Qualitative interview protocol
Needs assessment
1. First, can you tell me a little about your nation’ss t r a -
tegies to advance liver cancer prevention, treatment and
research?
2. What do you see as the main gaps in public policy
in your nation?
Aide memoire
a. Gaps at the national or federal
b. Interaction at the international level
c. Supporting patient advocacy efforts
d. Public educations and preventions strategies
e. Funding and organization
3. I would now like to focus on your nation’s current
needs for infrastructure associated with liver cancer pre-







4. Let us now focus on your nation’s current educa-








5. Can we talk now about any evidence gaps that exist
in your nation relating to liver cancer?
Aide memoire
a. Prevalence/surveillance
b. Burden of disease
c. Effective and cost effective prevention strategies
d. Effective and cost effective treatment strategies
e. National or international guidelines
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